

... first isolated from the seeds of the squirting cucumber has been engineered to bind selectively to tumor-associated integrin receptors. In their Communication on page 9894 ff., J. R. Cochran and co-workers describe a knottin-gemcitabine conjugate that is over 40-times smaller than an antibody-drug conjugate. This approach for targeted drug delivery offers an alternative strategy for the treatment of resistant tumors, such as brain or pancreatic cancer.

WILEY-VCH